1. Buning H, Perabo L, Coutelle O, Quadt-Humme S, Hallek M. Recent developments in adeno-associated virus vector technology. J Gene Med 2008; 10: 717–733.
2. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006; 14: 316–327.
3. Lebherz C, Maguire A, Tang W, Bennett J, Wilson JM. Novel AAV serotypes for improved ocular gene transfer. J Gene Med 2008; 10: 375–382.
4. Schmidt M, Voutetakis A, Afione S, et al. Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J Virol 2008; 82: 1399–1406.
5. Blankinship MJ, Gregorevic P, Chamberlain JS. Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors. Mol Ther 2006; 13: 241–249.
6. Wang L, Herzog RW. AAV-mediated gene transfer for treatment of hemophilia. Curr Gene Ther 2005; 5: 349–360.
7. Buch PK, Bainbridge JW, Ali RR. AAV-mediated gene therapy for retinal disorders: from mouse to man. Gene Ther 2008; 15: 849–857.
8. Moss RB, Milla C, Colombo J, et al. Repeated aerosolized AAV- CFTR for treatment of cystic fibrosis: a randomized placebo- controlled phase 2B trial. Hum Gene Ther 2007; 18: 726–732.
9. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342–347.
10. McPhee SW, Janson CG, Li C, et al. Immune responses to AAV in a phase I study for Canavan disease. J Gene Med 2006; 8: 577–588.
11. Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr Gene Ther 2007; 7: 316–324.
12. Erles K, Sebokova P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 1999; 59: 406–411.
13. Halbert CL, Miller AD, McNamara S, et al. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Hum Gene Ther 2006; 17: 440–447.
14. Mingozzi F, Maus MV, Hui DJ, et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 2007; 13: 419–422.
15. Zaiss AK, Muruve DA. Immune responses to adeno-associated virus vectors. Curr Gene Ther 2005; 5: 323–331.
16. Wang Z, Allen JM, Riddell SR, et al. Immunity to adenoassociated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther 2007; 18: 18–26.
17. Yuasa K, Yoshimura M, Urasawa N, et al. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products. Gene Ther 2007; 14: 1249–1260.
18. Cao O, Dobrzynski E, Wang L, et al. Induction and role of regulatory CD4 + CD25+ T cells in tolerance to the transgene 
19. Riviere C, Danos O, Douar AM. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther 2006; 13: 1300–1308.
20. Streilein JW. Ocular immune privilege: therapeutic opportuni- ties from an experiment of nature. Nat Rev Immunol 2003; 3: 879–889.
21. Yamagami S, Kawashima H, Tsuru T, et al. Role of Fas–Fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants. Transplantation 1997; 64: 1107–1111.
22. Jorgensen A, Wiencke AK, la CM, et al. Human retinal pigment epithelial cell-induced apoptosis in activated T cells. Invest Ophthalmol Vis Sci 1998; 39: 1590–1599.
23. Camelo S, Kezic J, McMenamin PG. Anterior chamber- associated immune deviation: a review of the anatomical evidence for the afferent arm of this unusual experimental model of ocular immune responses. Clin Experiment Ophthalmol 2005; 33: 426–432.
24. Sonoda KH, Sakamoto T, Qiao H, et al. The analysis of systemic tolerance elicited by antigen inoculation into the vitreous cavity: vitreous cavity-associated immune deviation. Immunology 2005; 116: 390–399.
25. Schlichtenbrede FC, da CL, Stephens C, et al. Long-term evaluation of retinal function in Prph2Rd2/Rd2 mice following AAV-mediated gene replacement therapy. J Gene Med 2003; 5: 757–764.
26. Kjellstrom S, Bush RA, Zeng Y, Takada Y, Sieving PA. Retinoschisin gene therapy and natural history in the Rs1h- KO mouse: long-term rescue from retinal degeneration. Invest Ophthalmol Vis Sci 2007; 48: 3837–3845.
27. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med 2008; 358: 2231–2239.
28. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med 2008; 358: 2240–2248.
29. Pang JJ, Chang B, Hawes NL, et al. Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA). Mol Vis 2005; 11: 152–162.
30. Mistry AR, De AM, Feudner E, Ali RR, Thrasher AJ. High-titer stocks of adeno-associated virus from replicating amplicons and herpes vectors. Methods Mol Med 2002; 69: 445–460.
31. Rogers WO, Weaver CT, Kraus LA, et al. Visualization of antigen-specific T cell activation and cytokine expression in vivo. J Immunol 1997; 158: 649–657.
32. Leonard WJ, Kronke M, Peffer NJ, Depper JM, Greene WC. Interleukin 2 receptor gene expression in normal human T lymphocytes. Proc Natl Acad Sci USA 1985; 82: 6281–6285.
33. Kim HP, Imbert J, Leonard WJ. Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev 2006; 17: 349–366.
34. Sancho D, Gomez M, Sanchez-Madrid F. CD69 is an immunoregulatory molecule induced following activation. Trends Immunol 2005; 26: 136–140.
35. Testi R, D’Ambrosio D, De MR, Santoni A. The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. Immunol Today 1994; 15: 479–483.
36. Boulanger A, Liu S, Yu S, Redmond TM. Sequence and structure of the mouse gene for RPE65. Mol Vis 2001; 7: 283–287.
37. Bennicelli J, Wright JF, Komaromy A, et al. Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther 2008; 16: 458–465.
38. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003; 4: 346–358.
39. Petry H, Brooks A, Orme A, et al. Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice. Gene Ther 2008; 15: 54–60.
40. Bennett J. Immune response following intraocular delivery of recombinant viral vectors. Gene Ther 2003; 10: 977–982.
41. Chen J, Wu Q, Yang P, Hsu HC, Mountz JD. Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX Gene Therapy. Mol Ther 2006; 13: 260–269.
42. McTiernan CF, Mathier MA, Zhu X, et al. Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts. Gene Ther 2007; 14: 1613–1622.
43. Vandenberghe LH, Wang L, Somanathan S, et al. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat Med 2006; 12: 967–971.
44. Perabo L, Goldnau D, White K, et al. Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism. J Virol 2006; 80: 7265–7269.
45. Jiang H, Couto LB, Patarroyo-White S, et al. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver- directed gene transfer in rhesus macaques and implications for human gene therapy. Blood 2006; 108: 3321–3328.
46. Wang Z, Kuhr CS, Allen JM, et al. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther 2007; 15: 1160–1166.